The active ingredient in Ozempic was associated with a reduced risk of Alzheimer's disease-related dementia among diabetes patients.

Beyond helping diabetes patients lose weight and control blood sugar, semaglutide appears to cut dementia risk by nearly half ...

With the launch of Wegovy by Danish pharmaceutical giant Novo Nordisk and US major Eli Lilly’s Mounjaro already in ...

A large study led by researchers at Case Western Reserve University suggests that semaglutide—a drug already popular for ...

A blockbuster diabetes and weight-loss drug might be doing more than controlling blood sugar—it could also be protecting the ...

A new study involving nearly 1.7 million patients suggests that semaglutide — a drug that mimics a gut hormone to lower blood sugar and aid weight loss — could significantly cut dementia risk in older ...

Wegovy, a weight-loss injection containing semaglutide, has arrived in India, offering a new approach to combatting obesity ...

A clinical trial found that weekly doses of semaglutide – a medication typically prescribed to Type 2 diabetes patients – ...

A massive U.S. study found diabetics on semaglutide (Ozempic’s active ingredient) had up to 70% lower risk of ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

An analysis of 1.7 million patients shows semaglutide may significantly reduce Alzheimer and vascular dementia risk compared ...